Suppr超能文献

COVID-19 第一波期间住院患者的抗生素使用与细菌感染:一项对 64691 例患者的回顾性队列研究。

Antibiotic Use and Bacterial Infection among Inpatients in the First Wave of COVID-19: a Retrospective Cohort Study of 64,691 Patients.

机构信息

Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Maryland VA Health Care System, Baltimore, Maryland, USA.

出版信息

Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0134121. doi: 10.1128/AAC.01341-21. Epub 2021 Sep 7.

Abstract

Hospitalized patients with SARS-CoV-2 infection (COVID-19) often receive antibiotics for suspected bacterial coinfection. We estimated the incidence of bacterial coinfection and secondary infection in COVID-19 using clinical diagnoses to determine how frequently antibiotics are administered when bacterial infection is absent. We performed a retrospective cohort study of inpatients with COVID-19 present on admission to hospitals in the Premier Healthcare Database between April and June 2020. Bacterial infections were defined using ICD-10-CM diagnosis codes and associated "present on admission" coding. Coinfections were defined by bacterial infection present on admission, while secondary infections were defined by bacterial infection that developed after admission. Coinfection and secondary infection were not mutually exclusive. A total of 18.5% of 64,961 COVID-19 patients ( = 12,040) presented with bacterial infection at admission, 3.8% ( = 2,506) developed secondary infection after admission, and 0.9% ( = 574) had both; 76.3% ( = 49,551) received an antibiotic while hospitalized, including 71% of patients who had no diagnosis of bacterial infection. Secondary bacterial infection occurred in 5.7% of patients receiving steroids in the first 2 days of hospitalization, 9.9% receiving tocilizumab in the first 2 days of hospitalization, and 10.3% of patients receiving both. After adjusting for patient and hospital characteristics, bacterial coinfection (adjusted relative risk [aRR], 1.15; 95% confidence interval [CI], 1.11 to 1.20) and secondary infection (aRR 1.93; 95% CI, 1.82 to 2.04) were both independently associated with increased mortality. Although 1 in 5 inpatients with COVID-19 presents with bacterial infection, secondary infections in the hospital are uncommon. Most inpatients with COVID-19 receive antibiotic therapy, including 71% of those not diagnosed with bacterial infection.

摘要

住院的 SARS-CoV-2 感染(COVID-19)患者常因疑似细菌合并感染而接受抗生素治疗。我们使用临床诊断来估计 COVID-19 中的细菌合并感染和继发感染的发生率,以确定在不存在细菌感染时抗生素的使用频率。我们对 2020 年 4 月至 6 月期间在 Premier Healthcare Database 中的入院 COVID-19 住院患者进行了回顾性队列研究。细菌感染使用 ICD-10-CM 诊断代码和相关的“入院时存在”编码来定义。合并感染定义为入院时存在细菌感染,继发感染定义为入院后发生的细菌感染。合并感染和继发感染不是互斥的。共有 18.5%(64961 例中的 12040 例)COVID-19 患者入院时存在细菌感染,3.8%(2506 例)在入院后发生继发感染,0.9%(574 例)同时存在这两种感染;76.3%(49551 例)在住院期间接受了抗生素治疗,包括 71%的患者没有细菌感染的诊断。在住院的前 2 天内接受类固醇治疗的患者中,继发细菌性感染的发生率为 5.7%,在前 2 天内接受托珠单抗治疗的患者中,继发细菌性感染的发生率为 9.9%,同时接受这两种药物治疗的患者中,继发细菌性感染的发生率为 10.3%。在调整了患者和医院特征后,细菌合并感染(调整后的相对风险 [aRR],1.15;95%置信区间 [CI],1.11 至 1.20)和继发感染(aRR,1.93;95%CI,1.82 至 2.04)都与死亡率增加独立相关。尽管 COVID-19 住院患者中有 1/5 存在细菌感染,但医院内的继发感染并不常见。大多数 COVID-19 住院患者接受抗生素治疗,包括 71%的未诊断为细菌感染的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8743/8522758/0250a4f49f83/aac.01341-21-f001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验